Brasada Capital Management LP Raises Position in Solventum Co. (NYSE:SOLV)

Brasada Capital Management LP boosted its stake in shares of Solventum Co. (NYSE:SOLV - Free Report) by 680.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 70,246 shares of the company's stock after acquiring an additional 61,246 shares during the quarter. Brasada Capital Management LP's holdings in Solventum were worth $4,795,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. MML Investors Services LLC boosted its holdings in shares of Solventum by 3.2% during the third quarter. MML Investors Services LLC now owns 5,345 shares of the company's stock worth $373,000 after purchasing an additional 168 shares during the period. Virtu Financial LLC purchased a new stake in Solventum in the 3rd quarter worth approximately $568,000. Wilmington Savings Fund Society FSB grew its position in shares of Solventum by 196.7% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 17,062 shares of the company's stock worth $1,190,000 after buying an additional 11,312 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of Solventum by 3.0% during the third quarter. Principal Financial Group Inc. now owns 169,615 shares of the company's stock valued at $11,826,000 after buying an additional 4,896 shares during the period. Finally, GAMMA Investing LLC increased its stake in shares of Solventum by 35.3% during the fourth quarter. GAMMA Investing LLC now owns 3,329 shares of the company's stock valued at $220,000 after buying an additional 868 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on SOLV. The Goldman Sachs Group boosted their price objective on shares of Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a research report on Monday, March 3rd. Mizuho boosted their price target on shares of Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a research report on Monday, March 3rd. Bank of America increased their price target on shares of Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 26th. Piper Sandler lifted their price objective on Solventum from $75.00 to $84.00 and gave the company a "neutral" rating in a research report on Friday, February 28th. Finally, Morgan Stanley increased their target price on Solventum from $73.00 to $80.00 and gave the stock an "equal weight" rating in a research report on Wednesday, March 5th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $79.86.

Solventum Stock Down 0.9 %

Shares of SOLV traded down $0.63 during mid-day trading on Monday, reaching $65.45. The company had a trading volume of 306,176 shares, compared to its average volume of 1,298,170. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The company has a market capitalization of $11.32 billion and a price-to-earnings ratio of 23.81. The firm has a 50-day moving average price of $72.58 and a 200 day moving average price of $71.60. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $85.92.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.